Theranexus SA logo

ALTHX - Theranexus SA News Story

€3.45 0.3  8.0%

Last Trade - 21/01/22

Sector
Healthcare
Size
Micro Cap
Market Cap £13.2m
Enterprise Value £6.58m
Revenue £n/a
Position in Universe 737th / 851

BRIEF-Theranexus Obtains IND Status In The U.S. To Start Clinical Development Of BBDF 101

Thu 9th September, 2021 5:15pm
Sept 9 (Reuters) - Theranexus SA  ALTHX.PA :
    * WITH THE BEYOND BATTEN DISEASE FOUNDATION (BBDF) OBTAINS
INVESTIGATIONAL NEW DRUG (IND) STATUS IN US TO START CLINICAL
DEVELOPMENT OF BBDF 101
    * APPROVAL FROM FDA TO LAUNCH A PHASE I/II CLINICAL TRIAL OF
DRUG
CANDIDATE BBDF 101 FOR JUVENILE BATTEN DISEASE
    * CLINICAL PROGRAM TO START WITH PHASE I/II BY THE END OF
2021

Source text for Eikon:  ID:nACT70926 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.